BJ-001(Boji Biomedical Technology)

N/A

Report date: 2022/01/17 12:14:22

Base Information

Drug NameBJ-001(Boji Biomedical Technology)
Drug Alias NameBJ-001 注射液tumor-targeting IL-15 fusion proteinBJ-001
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionInterleukin-15 receptor subunit alpha agonistsInterleukin-2 receptor beta chain agonistsInterleukin-2 receptor subunit gamma agonists
TargetsInterleukin-15 receptor subunit alphaInterleukin-2 receptor beta chainInterleukin-2 receptor subunit gamma
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCommunicable Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBoji Biomedical Technology (Hangzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBoji Biomedical Technology (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisCommunicable Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A